CV Sciences, Inc. · OTC:CVSI
CV Sciences — LDMicro Invitational Conference 2016
18 slides from CV Sciences's conference presentation, Jun 8, 2016
Slide 1: Drug Development Program Overview
Drug Development Program Overview LDMicro Invitational Conference June 8, 2016
Slide 2: Safe Harbor and Disclaimer
Safe Harbor and Disclaimer Safe Harbor: This presentation may contain certain forward - looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by
Slide 3: Corporate Overview
• Developing CBD based potential FDA approved drugs . • Manufacturing and marketing branded consumer products . Corporate Overview CV Sciences Inc . is a leader in marketed Cannabidiol (a) (CBD) products: 3 (a) Cannabidiol (or CBD) is a compound derived from Cannabis that is reported to potentially
Slide 4: Program Highlights: Overview of CBD Drug Development Program
Drug Development Program - Highlights • Initial Drug Candidate - ( CVS I - 007 ) chewing gum combines CBD and Nicotine - Patent Pending . • Proposed Claims - To support cessation of smokeless tobacco use/addiction . • Target Market - Smokeless tobacco market consisting of approximate $5.3 b illion i
Slide 5: Program - Unmet Need
Drug Development Program - Unmet Need 5 NO drug is FDA approved to support cessation of smokeless tobacco use and addiction . Urgent Unmet Medical Need: • Smokeless tobacco is carcinogenic (risk of esophageal, oral and pancreatic cancers) . 3 • Smokeless tobacco is strongly addictive . • Smokeless t
Slide 6: Program: Target Market
Drug Development Program : Target Market 6 Smokeless Tobacco Market • Approximately $5.3 billion annual US retail sales of smokeless tobacco products. 6 • Approximately 1.3 billion units of smokeless tobacco products sold annually in US. 6 • Approximately 9 million Americans use smokeless tobacco wi
Slide 7: Program: Tobacco Use Trends
Drug Development Program : Tobacco Use Trends 7 Sources: Euromonitor International 10 National Survey on Drug Use and Health Centers for Disease Control and Prevention
Slide 8: Program: Breaking Nicotine Addiction
Drug Development Program: Breaking Nicotine Addiction 8 Nicotine Anti Depressant Monoamine Oxidase (“ MAO “) Inhibitor Inhibition 11 Oral Stimulation Three Requirements for successfully treating nicotine addiction
Slide 9: Program: Initial Drug Candidate
Drug Development Pr ogram: Initial Drug Candidate 9 The initial drug candidate ( CVS I - 007 ) is a chewing gum containing Nicotine and CBD to support cessation of smokeless tobacco use and addiction . 1. CBD: to inhibit MAO and provide anti - depressant effect to replace tobacco alkaloids in pre -
Slide 10: FDA Approved Nicotine Drugs to Treat Smoking Addiction
FDA Approved Nicotine Drugs to Treat Smoking Addiction 10 Nicorette Nicotine Gum Mouth Spray Nicotine Lozenge Oral Spray Equate Nicotine Gum Nicotine Lozenge Habitrol Nicotine Gum Nicotine Lozenge Good Sense Nicotine Gum Nicotine Lozenge Nicoderm Nicotine Patch Nicotrol Nicotine Inhaler Nicotine Gum
Slide 11: Program: CBD as an Anti-Depressant Inhibitor
Drug Development Program: CBD as an Anti - Depressant Inhibitor 11 Proprietary In - Vitro Assay Demonstrates CBD as Antidepressant and MAO inhibition
Slide 12: Status of Drug Development Program
Status of Drug Development Program 12 Status Milestones Design of initial drug candidate Complete Formulation and production of proprietary CGMP synthetic CBD Complete In - vitro Assay of CBD as a MAO inhibitor Complete Finalization of internal Drug Development Program Complete Establisment of Drug
Slide 13: Status of FDA approval of CBD as an Active Drug Ingredient
Status of FDA approval of CBD as an Active Drug Ingredient Current regulatory environment for CBD as an FDA approved drug: • FDA Phase 3 human clinical trials of CBD are ongoing . • GW Pharma is seeking FDA approval for a CBD based drug based on a completed Phase 3 clinical trial . 12 • FDA approval
Slide 14: Team
Drug Development Team 14 CV Sciences has assembled a qualified and experienced team to lead its drug development program. Chief Medical Officer - Dr. Chris Chapman - Dr. Chapman serves as Chairman and Chief Executive Officer of Chapman Pharmaceutical Consulting, Inc., which provides expert medical c
Slide 15: Intellectual Property
Intellectual Property 15 • Proprietary cGMP formulation of Synthetic CBD for use in clinical trials. • Initial patent application (provisional) filed. • Banner and Wittcoff Ltd., Washington D.C. - patent counsel.
Slide 16: Financial Metrics
Financial Metrics Shares Outstanding 52M Public Float 36M Shareholders Equity (12/31/15) $23.3M FY 2015 Revenue $11.5M FY 2015 Adjusted EBITDA (a) ($ 2 . 3 M ) Market Cap ( 6 / 3 /16 ) $ 2 2 . 2 M Market: OTCQB (b) C VSI a) Adjusted EBITDA is defined as net income plus interest expense, income tax e
Slide 17: References
References References : 1. ClinicalTrials.gov, a service of the U.S. National Institutes of Health lists over 100 different studies utilizing Cannabidiol https://clinicaltrials.gov/ct2/results?term=cannabidiol&Search=Search 2. Statista, “Statistics and facts on smokeless tobacco in the U.S.”, http:/
Slide 18: Contact
Contact Joseph Dowling, CFO Tel: 866 - 290 - 2157 joseph.dowling@cvsciences.com 2688 S. Rainbow Boulevard, Suite B Las Vegas, NV 89146 cvsciences.com 18